

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences gets USFDA Nod for Generic Topical Anaesthetic Cream
Details : Lidocaine and Prilocaine cream is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery.
Product Name : EMLA-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Wanbang Biopharmaceuticals
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application
Details : Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.
Product Name : Senstend
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Wanbang Biopharmaceuticals
Deal Size : $4.0 million
Deal Type : Licensing Agreement
